| Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia E Yankova, W Blackaby, M Albertella, J Rak, E De Braekeleer, ... Nature 593 (7860), 597-601, 2021 | 863 | 2021 |
| The target landscape of clinical kinase drugs S Klaeger, S Heinzlmeir, M Wilhelm, H Polzer, B Vick, PA Koenig, ... Science 358 (6367), eaan4368, 2017 | 834 | 2017 |
| CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons A Martin-Villalba, I Herr, I Jeremias, M Hahne, R Brandt, J Vogel, ... Journal of Neuroscience 19 (10), 3809-3817, 1999 | 619 | 1999 |
| TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells I Jeremias, I Herr, T Boehler, KM Debatin European journal of immunology 28 (1), 143-152, 1998 | 410 | 1998 |
| TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB H Ehrhardt, S Fulda, I Schmid, J Hiscott, KM Debatin, I Jeremias Oncogene 22 (25), 3842-3852, 2003 | 395 | 2003 |
| Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation H Küster, M Weiss, AE Willeitner, S Detlefsen, I Jeremias, J Zbojan, ... The Lancet 352 (9136), 1271-1277, 1998 | 370 | 1998 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 354 | 2016 |
| Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia I Jeremias, C Kupatt, A Martin-Villalba, H Habazettl, J Schenkel, ... Circulation 102 (8), 915-920, 2000 | 350 | 2000 |
| Betulinic acid: a new cytotoxic agent against malignant brain‐tumor cells S Fulda, I Jeremias, HH Steiner, T Pietsch, KM Debatin International journal of cancer 82 (3), 435-441, 1999 | 316 | 1999 |
| Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells I Jeremias, C Kupatt, B Baumann, I Herr, T Wirth, KM Debatin Blood, The Journal of the American Society of Hematology 91 (12), 4624-4631, 1998 | 306 | 1998 |
| Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia S Ebinger, EZ Özdemir, C Ziegenhain, S Tiedt, CC Alves, M Grunert, ... Cancer cell 30 (6), 849-862, 2016 | 295 | 2016 |
| Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ... Leukemia 30 (2), 484-491, 2016 | 278 | 2016 |
| Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia S Göllner, T Oellerich, S Agrawal-Singh, T Schenk, HU Klein, C Rohde, ... Nature medicine 23 (1), 69-78, 2017 | 239 | 2017 |
| Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy A Moretti, L Fonteyne, F Giesert, P Hoppmann, AB Meier, T Bozoglu, ... Nature medicine 26 (2), 207-214, 2020 | 234 | 2020 |
| Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body C Pan, O Schoppe, A Parra-Damas, R Cai, MI Todorov, G Gondi, ... Cell 179 (7), 1661-1676. e19, 2019 | 208 | 2019 |
| Betulinic acid-induced apoptosis in leukemia cells H Ehrhardt, S Fulda, M Führer, KM Debatin, I Jeremias Leukemia 18 (8), 1406-1412, 2004 | 178 | 2004 |
| Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2–mediated resistance M Fakler, S Loeder, M Vogler, K Schneider, I Jeremias, KM Debatin, ... Blood, The Journal of the American Society of Hematology 113 (8), 1710-1722, 2009 | 174 | 2009 |
| MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199 JM Benito, L Godfrey, K Kojima, L Hogdal, M Wunderlich, H Geng, I Marzo, ... Cell reports 13 (12), 2715-2727, 2015 | 152 | 2015 |
| T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals N Philipp, M Kazerani, A Nicholls, B Vick, J Wulf, T Straub, M Scheurer, ... Blood, The Journal of the American Society of Hematology 140 (10), 1104-1118, 2022 | 141 | 2022 |
| Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR D Stenger, TA Stief, T Kaeuferle, S Willier, F Rataj, K Schober, B Vick, ... Blood, The Journal of the American Society of Hematology 136 (12), 1407-1418, 2020 | 140 | 2020 |